GoodRx Faces Q3 Print With Activist Owners, Shrinking Short Positions

GoodRx Holdings reports Q3 results on November 4, trading at $3.55 after a quiet month that saw shares gain just over 8% while short sellers retreated sharply from the stock.

The retreat in short interest is the clearest change in the setup. Shorts have covered roughly a quarter of their position over the past month, with SI falling to 3.4% of the free float from levels above 4.5% in early October. The lending market gives no reason for urgency on the other side either: availability is exceptionally loose at over 1,200%, meaning there are more than twelve shares available to borrow for every one already shorted. Borrowing costs remain negligible at 0.53%. Options positioning has nudged more defensive into the print, with the put/call ratio at 0.19 against a 20-day average closer to 0.16, but the z-score of roughly 2 reflects a modest drift rather than alarm. The overall picture from positioning is a stock that shorts have been quietly exiting, not one where either side is pressing hard.

The debate around GoodRx is between a cheap-on-paper recovery and a business still searching for a durable growth model. The forward earnings yield ranks in the 70th percentile of the universe, and the stock trades at roughly 10x trailing earnings and under 6x EV/EBITDA, multiples that would look attractive if revenue momentum holds. The 12-month forward EPS consensus has been revised up dramatically, placing that factor in the 93rd percentile. Against that, the company has missed expectations often enough to rank in only the 14th percentile on earnings surprise, and analyst sentiment is split: Citigroup, TD Cowen and Wells Fargo carry buy-equivalent ratings with targets between $5.00 and $5.00, while Barclays holds an Underweight at $4.00 and UBS stays at Neutral with a $3.75 target. All those moves followed the August print and are now several months old; no major firm has updated publicly in the six weeks since.

The ownership structure is a more unusual element of this story. GoodRx carries active Schedule 13D filings on its register, a fact that warrants attention. Francisco Partners GP IV, the largest declared holder, last disclosed a 32.9% stake in August after trimming from 36%, while the co-founders' vehicle Idea Men holds a further 29.1% (down from 32.3% as of March). Both Francisco Partners and the co-founder entities, including Douglas Hirsch and Trevor Bezdek individually, hold 13D activist classifications. That means the majority of the share register is held by parties who have formally declared an interest in influencing the company's direction. Hirsch made a small option exercise on October 26. The recent insider activity is predominantly stock-based compensation mechanics, vesting and tax-withholding transactions by executives in mid-October, not open-market conviction buying or selling. As always with 13D/G filings, stakes are as-last-disclosed and holders dropping below 5% may not file again. Francisco Partners' net reduction of 7.5 million shares since August is worth noting as a sign the private equity holder continues to trim.

The Q3 print will test whether the forward earnings revision story has any underlying revenue support, or whether the valuation re-rating of the past month is running ahead of what the numbers can justify.